Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISH0688 in Healthy Subjects and Patients with Hyperlipidemia/Hypertriglyceridemia
NCT07505043Phase 1Not yet recruiting
- Sponsor
- SUNHO BioPharmaceutical
- Start
- Mar 2026
- Primary completion
- Feb 2027
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ISH0688 in hyperlipidemia and hypertriglyceridemia (4 arms), sponsored by SUNHO BioPharmaceutical. Primary endpoints: Number of participants with treatment-emergent adverse events at day 84 and Injection site reactions assessments at day 84. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
ISH0688
03
Conditions
hyperlipidemiahypertriglyceridemia
Beyond the preview
Go deeper on NCT07505043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07505043.